title: Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
abstract: An 80-year-old patient with castrate-resistant prostate cancer presented to our department for PSMA imaging because of a rising prostate-specific antigen (PSA) level. The tumor was diagnosed in 2004. GnRh analog was the only treatment the patient received. Two cycles of Lu-PSMA-617 were performed with a 2-month interval in between. Ten months after finishing with 2 cycles of Lu-PSMA therapy, we noticed a continuous falling PSA level and a decreasing tumor spread in the PET/CT imaging just under the hormone therapy.
authors.affiliation: From the *Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany; and †Private Office for Urology, Bonn, Germany.
authors.forename: Carl Diedrich
authors.initials: CD
authors.lastname: Schlenkhoff
authors.forename: Eberhard
authors.initials: E
authors.lastname: Knüpfer
authors.forename: Markus
authors.initials: M
authors.lastname: Essler
authors.forename: Hojjat
authors.initials: H
authors.lastname: Ahmadzadehfar
mesh_terms: D000369:Aged, 80 and over; D004151:Dipeptides / Q000627:therapeutic use*; D006573:Heterocyclic Compounds, 1-Ring / Q000627:therapeutic use*; D006801:Humans; D008187:Lutetium / Q000627:therapeutic use*; D008297:Male; D009362:Neoplasm Metastasis; D000072078:Positron Emission Tomography Computed Tomography; D017430:Prostate-Specific Antigen; D064129:Prostatic Neoplasms, Castration-Resistant / Q000000981:diagnostic imaging / Q000473:pathology* / Q000532:radiotherapy*; D011868:Radioisotopes; D016896:Treatment Outcome
chemical_list: D004151:Dipeptides; D006573:Heterocyclic Compounds, 1-Ring; C000602389:PSMA-617; D011868:Radioisotopes; D008187:Lutetium; D017430:Prostate-Specific Antigen